Plaque busters: Strategies to inhibit amyloid formation in Alzheimer's disease

Molecular Medicine Today

Volumn 5, Issue 8, 1999, Pages 343-350

  Soto, Claudio ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTHRACYCLINE 4' IODO 4' DEOXYDORUBICIN; APOLIPOPROTEIN E; BENZOFURAN DERIVATIVE; CONGO RED; ESTROGEN; HEXADECYL N METHYLPIPERIDINIUM; MELATONIN; NICOTINE; PRESENILIN 1; PRESENILIN 2; PROTEIN INHIBITOR; RIFAMPICIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DRUG MECHANISM; GENE THERAPY; HUMAN; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PROTEIN PROCESSING; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID; BRAIN; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY; SENILE PLAQUES;

EID: 0032839878     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01508-7     Document Type: Review

References (50)

1. Terry, R.D. (1994) Neuropathological changes in Alzheimer's disease, Prog. Brain Res. 101, 383-390
2. Selkoe, D.J. (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease, Trends CellBiol. 8, 447-453
3. Muller-Hill, B. and Beyreuther, K. (1989) Molecular biology of Alzheimer's disease, Anna. Rev. Biochem. 58, 287-307
4. Mann, D.M. (1989) Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome, Neurobiol. Aging 10, 397-399
5. Hardy, J. and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease, Trends Pharmacol. Sci. 12, 383-388
6. Price, D.L and Sisodia, S.S. (1998) Mutant genes in familial Alzheimer's disease and transgenic models, Anna. Rev. Neurosci. 21, 479-505
7. Younkin, S.O. (1995) Evidence that A 42 is the real culprit in Alzheimer's disease, Ann. Neural. 37, 287-288
8. Wisniewski, T., Ghiso, J. and Frangione, B. (1994) Alzheimer's disease and soluble \$, Neurobiol. Aging 15, 143-152
9. Higgins, L.S. (1999) Animal models of Alzheimer's disease, Mol. Med. Today 5, 274-276
10. Haass, C. et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism, Nature 359, 322-325
11. Seubert, P. et al. (1992) Isolation and quantification of soluble Alzheimer's betapeptide from biological fluids, Nature 359, 325-327
12. Shoji, M. étal. (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258, 126-129
13. Zheng, H. étal. (1995) p-amyloid precursor protein deficient mice show reactive gliosis and decreased locomotor activity, Cell 81, 525-533
14. Soto, C., Branes, M.C., Alvarez, J. and Inestrosa, N.C. (1994) Structural determinants of the Alzheimer's amyloid beta-peptide, J. Neurochem. 63, 1191-1198
15. Teplow, D.B. (1998) Structural and kinetic features of amyloid beta-protein fibrillogenesis.Amj/oiWS, 121-142
16. Lorenzo, A. and Yankner, B.A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red, Proc. Natl. Acad. Sci. U. S. A. 91, 12243-12247
17. Yankner, B.A. (1996) Mechanisms of neuronal degeneration in Alzheimer's disease, Neuron 16, 921-932
18. Hilbich, C. et al. (1992) Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease A4 peptides, J. Mol. Biol. 228, 460-473
19. Jarrett, J.T., Berger, EP. and Lansbury, P.T., Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease, Biochemistry 32, 4693-4697
20. Barrow, C.J., Yasuda, A., Kenny, P.T. and Zagorski, M.G. (1992) Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra, J. Mol. Biol. 225, 1075-1093
21. Soto, C., Castano, E.M., Frangione, B. and Inestrosa, N.C. (1995) The alpha-helical to beta-strand transition in the ammo-terminal fragment of the amyloid beta-peptide modulates amyloid formation, J. Biol. Chem. 270, 3063-3067
22. Soto, C. and Castano, E.M. (1996) The conformation of Alzheimer's peptide determines the rate of amyloid formation and its resistance to proteolysis, Biochem. J. 314, 701-707
23. Maggio, J.E. and Mantyh, PAY. (1996) Brain amyloid: a physicochemical perspective, Brain Palhol. 6, 147-162
24. Wood, J.D., Wetzel, R., Martin, J.D. and Hurle, M.R. (1995) Prolines and amyloidogenicity in Fragments of the Alzheimer's peptide /A4, Biochemistry 34, 724-730
25. Tjernberg, L.O. et al. (1996) Arrest of -amyloid fibril formation by a pentapeptide ligand, J. Biol. Chem. 271, 8545-8548
26. El-Agnaf, O.M., Guthrie, D.J., Walsh, D.M. and Irvine, G.B. (1998) The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide, Eur. J. Kochern. 256, 560-569
27. Wood, S.J. et al. (1996) Selective inhibition of Aβ fibril formation, J. Biol Chem. 271, 4086-4092
28. Kisilevsky, R. etal. (1995) Arresting amyloidosis in mo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease, Nat. Med. 1, 143-148
29. Allsop, D., Hewlett, D., Christie, G. and Karran, E. (1998) Fibrillogenesis of βamyloid, Biochem. Soc. Trans. 26, 459-463.
30. Tomiyama, T. et al. (1996) Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin - Its possible function as a hydroxyl radical scavenger, J. Biol. Chem. 271, 6839-6844
31. Pappolla, M. etal. (1998) Inhibition of Alzheimer β-fibrillogenesis by melatonin, J. Biol. Chem. 273, 7185-7188
32. Salomon, A.R., Mardnowski, K.J., Friedland, R. and Zagorski, M.G. (1996) Nicotine inhibits amyloid formation by the β-pcptide, Biochemistry 35, 13568-13578
33. Mook-Jung, I. et al. (1997) Estrogen blocks neurotoxic effects of beta-amyloid (1-42) and induces neurite extension in B103 cells, Neurosci. Lett. 235, 101-104
34. Merlini, G. et al. (1995) Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of fibrillogenesis, Proc. Natl. Acad. Sci. U. S. A. 92, 2959-2964
35. Solo, C-, Ghisb, J. and Frangione, B. (1997) Alzheimer's amyloid-β aggregation is modulated by the interaction of multiple factors, AlzJieimer s Res. 3, 215-222
36. Webster, S. and Rogers, J. (1996) Relative efficacies of amyloid-β peptide (Aβ) binding proteins in Aβ aggregation, J. Neurosci. Res. 46, 58-66
37. Golabek, A., Marques, M., Lalowski, M. and Wisniewski, T. (1995) Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid, Neurosci. Lett. 191, 79-82
38. Bales, K.R. et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition, Nat. Genet. 17, 254-256
39. Ghanta, J., Shen, C.L., Kiessling, L.L. and Murphy, R.M. (1996) A strategy for designing inhibitors of β-amyloid toxicity, J. Biol. Chem. 271, 29525-29528
40. Kelly, J.W. (1996) Alternative conformations of amyloidogenic proteins govern their behavior, Curr. Opin. Struct. Biol. 6, 11-17
41. Thomas, P.J., Qu, B-H. and Pedersen, P.L. (1995) Defective protein folding as a basis of human disease, Trends Biochem. Sci. 20, 456-459
42. Soto, C. Alzheimer's and prion diseases as disorders of protein conformation: design of novel therapeutic approaches, J. Mol. Med. (in press)
43. Soto, C., Kindy, M.S., Baumann, M. and Frangione, B. (1996) Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation, Biochem. Biophys. Res. Commun. 226, 672-680
44. Soto, C. et al (1998) β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy, Nat. Med. 4, 822-826
45. Wouters, M.A. and Curmi, P.M.G. (1994) An analysis of side chain interactions and pair correlations within antiparallel beta sheets: the differences between backbone hydrogen-bonded and non-hydrogen bonded residue pairs, Protein Sci. 3.43S
46. Poduslo, J.F. et al. ( 1999) β-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma, J. Neurobiol. 39, 371-382
47. Abagyan, R.A., Totrov, M.M. and Kuznetsov, D.A. (1994) ICM: a new method for structure modeling and design: applications to docking and structure prediction from the distorted native conformation, J. Comp. Chem. 15, 488-506
48. Stricht, H. et al. (1995) Structure of amyloid A4-(l-40)-peptide of Alzheimer's disease, Ear. J. Biochem. 233, 293-298
49. Lee, J.P. et al (1995) H-l NMR of A-beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence, Biochemistry 34, 5191-5200
50. Benzinger, T.L.S. et al (1998) Propagating structure of Alzheimer's β-amyloid (10-35) is parallel β sheet with residues in exact register, Proc. Natl. Acad. Sci. U. S. A. 95, 13407-13412